Neurological disorders: Cerebrovascular disease and Parkinsonism

Urologic Clinics of North America

Volumn 30, Issue 1, 2003, Pages 27-47

  Siroky, Mike B ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston VA Healthcare ^*  (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ATROPINE; BENZATROPINE MESILATE; BROMOCRIPTINE; BUPIVACAINE; CAPSAICIN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DESMOPRESSIN; DOPAMINE RECEPTOR STIMULATING AGENT; IMIPRAMINE; LEVODOPA; LOCAL ANESTHETIC AGENT; OXYBUTYNIN; PERGOLIDE MESILATE; PRAMIPEXOLE; RESINIFERATOXIN; TERODILINE; TOLTERODINE;

AMNESIA; BLADDER CAPACITY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CYSTOMETRY; DETRUSOR DYSSYNERGIA; DIABETES INSIPIDUS; DIFFERENTIAL DIAGNOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; ELECTROMYOGRAPHY; FLUID RETENTION; HALLUCINATION; HEADACHE; HUMAN; HYPONATREMIA; MICTURITION; NEUROANATOMY; NEUROGENIC BLADDER; NEUROLOGIC DISEASE; NEUROPHYSIOLOGY; PARKINSONISM; PHYSICAL EXAMINATION; POLYURIA; PRIORITY JOURNAL; PROGNOSIS; RESIDUAL URINE; REVIEW; SHY DRAGER SYNDROME; SIDE EFFECT; SLEEP APNEA SYNDROME; SOMNOLENCE; URINE INCONTINENCE; URINE RETENTION; URODYNAMICS; UROFLOWMETRY; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTIPARKINSON AGENTS; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; DIAGNOSTIC TECHNIQUES, UROLOGICAL; FEMALE; HUMANS; MALE; PARKINSON DISEASE; URINATION; URINATION DISORDERS;

EID: 0037310179     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00114-3     Document Type: Review

References (167)

1. Barrington FJF. The relation of the hindbrain to micturition. Brain 1921;44:23.
2. deGroat WC. Anatomy and Physiology of the lower urinary tract. Urol Clin North Am 1993;20:383.
3. Habler HJ, Janig W, Koltzenburg M. Myelinated primary afferents of the sacral spinal cord responding to slow filling and distension of the cat urinary bladder. J Physiol 1993;463:449-60.
4. Floyd K, Hick VE, Morrison JF. Mechanosensitive afferent units in the hypogastric nerve of the cat. J Physiol 1976;259:457-71.
5. Bayliss M, Wu C, Newgreen D, et al. A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J Urol 1999;162:1833.
6. Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation of the urinary bladder: the possibility of transmission via nerves releasing a purine nucleotide. Br J Pharmacol 1972;44:451.
7. Elbadawi A. Neuromorphologic basis of vesicourethral function. I. Histochemistry ultrastructure and function of intrinsic nerves of the bladder and urethra. Neurourol Urodyn 1982;1:3-50.
8. Gosling JA, Dixon JS, Lendon RG. The autonomic innervation of the human male and female bladder neck and proximal urethra. J Urol 1977;118:302-5.
9. Vera PL, Nadelhaft I. Anatomical evidence for two spinal 'afferent-interneuron-efferent' reflex pathways involved in micturition in the rat: a 'pelvic nerve' reflex pathway and a 'sacrolumbar intersegmental' reflex pathway. Brain Res 2000;803:107-18.
10. Duong M, Downie JW, Du HJ. Transmission of afferent information from urinary bladder, urethra and perineum to periaqueductal gray of cat. Brain Res 1999;819:108-19.
11. Blok BF, Holstege G. Two pontine micturition centers in the cat are not interconnected directly: implications for the central organization of micturition. J Comp Neurol 1999b;403:209-18.
12. Loewy AD, Saper CB, Baker RP. Descending projections from the pontine micturition center. Brain Res 1979;172:533-8.
13. Noto H, Roppolo JR, Steers WD, et al. Electrophysiological analysis of the ascending and descending components of the micturition reflex pathway in the rat. Brain Res 1991;549:95-105.
14. Blok BFM, De Weerd H, Holstege G. Ultrastructural evidence for the paucity of projections from the lumbosacral cord to the M-region in the cat. A new concept for the organization of the the micturition reflex with the periaqueductal gray as the central relay. J Comp Neurol 1995;359:300-9.
15. Matsuura S, Allen GV, Downie JW. Volume-evoked micturition reflex is mediated by the ventrolateral periaqueductal gray in anesthetized rats. Am J Physiol 1998;275:R2049-55.
16. Imada N, Koyama Y, Kawauchi A, et al. State dependent response of the locus caeruleus neurons to bladder distention. J Urol 2000;164:1740-4.
17. Yoshimura N, Sasa M, Yoshida O, Takaori S. Mediation of micturition reflex by central norepinephrine from the locus coeruleus in the cat. J Urol 1990;143:840-3.
18. Holstege G, Griffiths D, De Wall H, Dalm E. Anatomical and physiological observations on supraspinal control of bladder and urethral muscles in the cat. J Comp Neurol 1986;250:449-61.
19. Griffiths D, Holstege G, De Wall H, Dalm E. Control and coordination of bladder and urethral function in the brain stem of the cat. Neurourol Urodynam 1990;9:63-82.
20. Siroky MB, Krane RJ. Neurologic aspects of detrusor hyperreflexia with reference to the guarding reflex. J Urol 1982;127:953-7.
21. Sato M, Mizuno N, Konishi A. Localization of motoneurons innervating perineal muscles: a HRP study in the cat. Brain Res 1978;140:149-54.
22. Zermann DH, Ishigooka M, Doggweiler R, Schmidt RA. Central autonomic innervation of the lower urinary tract-a neuroanatomy study. World J Urol 1998;16:417-22.
23. Gjone R. Excitatory and inhibitory bladder responses to stimulation of 'limbic', diencephalic and mesencephalic structures in the cat. Acta Physiol Scand 1966;66:91-102.
24. Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 2001;124:369-77.
25. Blok BF, Willemsen AT, Holstege G. A PET study on brain control of micturition in humans. Brain 1997;120:111-21.
26. Blok BF, Sturms LM, Holstege G. Brain activation during micturition in women. Brain 1998;121:2033-42.
27. Kanie S, Yokoyama O, Komatsu K, et al. GABAergic contribution to rat bladder hyperactivity after middle cerebral artery occlusion. Am J Physiol Regul Integr Comp Physiol 2000;279:R1230-8.
28. Mallory BS, Roppolo JR, de Groat WC. Pharmacological modulation of the pontine micturition center. Brain Res 1991;546:310-20.
29. Sillen U. Central neurotransmitter mechanisms involved in the control of urinary bladder function. An experimental study in the rat. Scand J Urol Nephrol Suppl 1980(Suppl);58:1-45.
30. Seki S, Igawa Y, Kaidoh K. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn 2001;20:105-13.
31. Bhatia NN, Bradley WE. Neuroanatomy and physiology: innervation of the urinary tract. In: Raz S, editor. Female Urology. Philadelphia: WB Saunders; 1983. p. 12-32.
32. Blok BFM, Holstege G. The central control of micturition and continence: implications for urology. BJU International 1999a;83(Suppl 2):1-6.
33. Holstege G. Some anatomical observations on the projections from the hypothalamus to brainstem and spinal cord: an HRP and autoradiographic tracing study in the cat. J Comp Neurol 1987;260:98-126.
34. Finkbeiner AE. In vitro responses of detrusor smooth muscle to stretch and relaxation. Scand J Urol Nephrol Supl 1999;201:5-11.
35. Coolsaet BLRA. Cystometry. In: Stanton SL, editor. Clinical Gynecologic Urology. St Louis: Mosby; 1984. p. 59-81.
36. Espey MJ, Du HJ, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998;798:101-8.
37. Lee JG, Wein AJ, Levin RM. Comparative pharmacology of the male and female rabbit bladder neck and urethral involvement of nitric oxide. Pharmacology 1994b;250-9.
38. Mevorach RA, Bogaert GA, Kogan BA. Role of nitric oxide in fetal lower urinary tract function. J Urol 1994;152:510.
39. Sax D. History and Physical Examination in Neuro-Urology, Ch 4. In: Krane RJ, Siroky MB, editors. Clinical Neuro-Urology. Boston: Little, Brown & Company; 1979;63-7.
40. Blaivas JG, Zayed AA, Labib KB. The bulbocavernosus reflex in urology: a prospective study of 299 patients. J Urol 1981;126:197-9.
41. Siroky MB. Interpretation of urinary flow rates. Urol Clin North Am 1990;17:537-42.
42. Chancellor M, Blaivas J, Kaplan S, et al. Bladder outlet obstruction versus impaired detrusor contractility: the role of uroflow. J Urol 1991;145:810.
43. Ghonheim G. Impaired bladder contractility in association with detrusor instability: underestimated occurrence in benign prostatic hyperplasia. Neurourol Urodyn 1991;10:111.
44. Lapides J, Friend ER, Ajemian EP. Denervation supersensitivity as a test for neurogenic bladder. Surg Gynecol Obstet 1962;114:241-4.
45. Pavlakis AJ, Siroky MB, Krane RJ. Neurogenic detrusor areflexia: correlation of perineal electromyography and bethanechol chloride supersensitivity testing. J Urol 1983b;129:1182-4.
46. Siroky MB. Electromyography of the perineal floor. Urol Clin North Am 1996;23:299-307.
47. Siroky MB. Clinical characteristics of pseudo-dyssynergia. Neurourol and Urodynam 1986;5:317.
48. Wein A, Barrett DM. Etiologic possibilities of increased pelvic floor electromyographic activity during cystometry. J Urol 1982;127:949.
49. Lutsep HL, Albers GW, DeCrespigny A, et al. Clinical utility of diffusion-weighted magnetic resonance imaging in the assessment of ischemic stroke. Ann Neurol 1997;41:574-80.
50. Fisher M, Prichard JW, Warach S. New magnetic resonance techniques for acute ischemic stroke. JAMA 1995 Sep 20;274(11):908-11.
51. Murri L, Gori S, Massetani R, Bonanni E, Marcella F, Milani S. Evaluation of acute ischemic stroke using quantitative EEG: a comparison with conventional EEG and CT scan. Neurophysiol Clin 1998 Jun;28(3):249-57.
52. Fieschi C, Argentino C, Lenzi GL, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci 1989;91:311.
53. Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001;32:2559-66.
54. Yatsu FM, Grotta JC, Villar-Cordova C. Cerebrovascular disorders. In: Dale DC, Federman DD, editors. Scientific American Medicine. Scientific American 1997;4:1.
55. Brittain KR, Peet SM, Castleden CM. Stroke and incontinence. Stroke 1998;29:524-8.
56. Carrieri PB, Orefice G, Maiorino A, et al. Age-related risk factors for ischemic stroke in Italian men. Neuroepidemiology 1994;13:28-33.
57. Yokoyama O, Komatsu K, Ishiura Y. Change in bladder contractility associated with bladder overactivity in rats with cerebral infarction. J Urol 1998;159:577-80.
58. Yokoyama O, Yoshiyama M, Namiki M, de Groat WC. Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion. Am J Physiol 1999;276:R935-42.
59. Burney TL, Senapati M, Desai S, et al. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol 1996;156:1748.
60. Khan Z, Starer P, Yang WC, et al. Analysis of voiding disorders in patients with cerebrovascular accidents. Urology 1990;35:265.
61. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996a;137:47-56.
62. Tsuchida S, Noto H, Yamaguchi O, et al. Urodynamic studies on hemiplegic patients after cerebrovascular accident. Urology 1983;21:315.
63. Badlani GH, Vohara S, Motola JA. Detrusor behavior in patients with dominant hemispheric strokes. Neurourol Urodyn 1991;10:119.
64. Gelber DA, Good DC, Laven LJ, et al. Causes of urinary incontinence after acute hemispheric stroke. Stroke 1993;24:378-82.
65. Khan Z, Hertanu J, Yang WC, et al. Predictive correlation of urodynamic dysfunction and brain injury after cerebrovascular accident. J Urol 1981;126:86.
66. Kuroiwa Y, Tohgi H, Ono S, Itoh M. Frequncy and urgency of micturition in hemiplegic patients: relationship to hemisphere laterality of lesions. J Neurol 1987;234:100-2.
67. Nakayama H, Jorgensen HS, Pedersen PM, et al. Prevalence and risk factors of incontinence after stroke: the Copenhagen stroke study. Stroke 1997;28:58-62.
68. Arunabh, Badlani GH. Urologic problems in cerebrovascular accidents. Problems in urology 1993;7:41.
69. Sakakibara R, Shinotoh H, Uchiyama T, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 2001;92:76-85.
70. Brockelhurst JC, Andrews K, Richards B, et al. Incidence and correlates of incontinence in stroke patients. J Am Geriatr Soc 1985;33:540-2.
71. Borrie MJ, Campbell AJ, Caradoc-Davies TH, Spears GF. Urinary incontinence after stroke: a prospective study. Age Ageing 1986;15:177-81.
72. Taub NA, Wolfe CD, Richardson E, et al. Predicting the disability of first-time stroke sufferers at 1 year. 12-Month follow-up of a population-based cohort in Southeast England. Stroke 1994;25:352.
73. Ween JE, Alexander MP, D'Esposito M, Roberts M. Incontinence after stroke in a rehabilitation setting: outcome associations and predictive factors. Neurology 1996;47:659-63.
74. Korpelainen JT, Nieminen P, Myllyla VV. Sexual functioning among stroke patients and their spouses. Stroke 1999 Apr;30(4):715-9.
75. Andersen JT, Bradley WE. Cystometric, sphincter and electromyelographic abnormalities in Parkinson's disease. J Urol 1976;116:75-8.
76. Nitti VW, Adler H, Combs AJ. The role of urodynamics in the evaluation of voiding dysfunction in men after cerebrovascular accident. J Urol 1996;155:263-6.
77. Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function. An unrecognized but common cause of incontinence in elderly patients. JAMA 1987;257:3076.
78. Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med 1989;320:1-7.
79. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance and the pontine tegmental lesion: urodynamic and MRI analyses of vascular cases. J Neurol Sci 1996b;141:105-10.
80. Patel M, Coshall C, Lawrence E. Recovery from poststroke urinary incontinence: associated factors and impact on outcome. J Am Geriatr Soc 2001;49:1229-33.
81. Jeter KF, Lutz JB. Skin care in the frail, elderly, dependent, incontinent patient. Adv Wound Care 1996;9:29-34.
82. Davenport RJ, Dennis MS, Wellwood I, Warlow CP. Complications after acute stroke. Stroke 1996;27:415-20.
83. Steers WD, Lee KS. Depression and incontinence. World J Urol 2001;19:351-7.
84. Stewart RB, Moore MT, May FE, et al. Nocturia: a risk factor for falls in the elderly. J Am Geriatr Soc 1992;40:1217.
85. Middlekoop HA, Smilde-van den Doel DA, Neven AK, et al. Subjective sleep characteristics of 1,485 males and females aged 50-93: effects of sex and age, and factors related to self-evaluated quality of sleep. J Gerontol 1996;51:M108.
86. Matthiesen TB, Rittig S, Norgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996;156:1292.
87. Marinkovic S, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol 2001;165:359-70.
88. Weiss JP, Stember DS, Chaikin DC, et al. Evaluation of the etiology of nocturia in men: the nocturia and nocturnal bladder capacity indices. Neurourol Urodyn 1999;18:559.
89. Weiss JP, Blaivas JG. Nocturia. J Urol 2000;163:5-12.
90. Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998;81:215.
91. Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in elderly subjects with nocturia. Med Sci Res 1991;19:765.
92. Asplund R, Aberg H. Desmopressin in elderly subjects with increased nocturnal diuresis. A two-month treatment study. Scand J Urol Nephrol 1993;27(1):77-82.
93. Hunsballe JM, Rittig S, Pederson EB, et al. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol 1997;158:830.
94. Tomasi PA, Siracusano S, Monni AM, et al. Decreased nocturnal urinary antidiuretic hormone excretion in enuresis is increased by imipramine. BJU Int 2001;88:932-7.
95. Partinen M. Epidemiology of obstructive sleep apnea syndrome. Curr Opin Pulm Med 1995a;1:482-7.
96. Partinen M. Ischaemic stroke, snoring and obstructive sleep apnoea. J Sleep Res 1995b;4:156-9.
97. Hildebrandt W, Ottenbacher A, Schuster M, et al. Diuretic effect of hypoxia, hypocapnia, and hyperpnea in humans: relation to hormones and O(2) hemosensitivity. J Appl Physiol 2000Feb;88(2):599-610.
98. Swenson ER, Duncan TB, Goldberg SV, et al. Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones. J Appl Physiol 1995;78:377-83.
99. Yarker YE, Goa KL, Fitton A. Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-62.
100. Ouslander JG, Blaustein J, Connor A, et al. Pharmacokinetics and clinical effects of oxybutynin in geriatric patients. J Urol 1988;140:47-50.
101. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica 1992 Jul;22(7):859-69.
102. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
103. Douchamps J, Derenne F, Stockis A, et al. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-20.
104. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997Mar;157(3):1093-7.
105. Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 1998;160:892-6.
106. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992;148:595-7.
107. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001;18:1029-34.
108. Gleason DM, Susset J, White C, et al. Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology 1999;54(3):420-3.
109. Sathyan G, Chancellor MB, Gupta SK. Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001 Oct;52(4):409-17.
110. Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol 2001;19:312-8.
111. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60.
112. Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-6.
113. Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 2001;18(4):277-304.
114. Van Kerrebroeck PE, Amarenco G, Thüroff JW,et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998;17:499.
115. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-63.
116. Eardley I, Quinn NP, Fowler CJ, Kirby RS, Parkhouse HF, Marsden CD, Bannister R. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989Oct;64(4):360-2.
117. Lose G, Norgaard JP. Intravesical oxybutynin for treating incontinence resulting from an overactive detrusor. BJU Int 2001 Jun;87(9):767-73.
118. Schroder A, Levin RM, Kogan BA, et al. Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder. Urology 2000;56:1063-7.
119. Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
120. Haferkamp A, Staehler G, Gerner HJ, Dorsam J. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients. Spinal Cord 2000;38:250-4.
121. Kasabian N, Vlachiotis J, Lais A, et al. The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J Urol 1994;151:944.
122. Enskat R, Deaney CN, Glickman S. Systemic effects of intravesical atropine sulphate. BJU Int 2001;87:613-6.
123. Glickman S, Tsokkos N, Shah PJ. Intravesical atropine and suppression of detrusor hypercontractility in the neuropathic bladder. A preliminary study. Paraplegia 1995;33:36-9.
124. Ekstrom B. Intravesical instillation of drugs in patients with detrusor hyperactivity. Scand J Urol Nephrol 1992;(Suppl)149:1-67.
125. Aragona F, di Tonno F, Prayer-Galetti T, et al. Vesical instillation of emepronium bromide in defunctionalized postobstructive noncompliant bladder: an alternative to intestinal augmentation surgery? Child Nephrol Urol 1990;10(1):39-43.
126. Fowler CJ. Intravesical treatment of overactive bladder. Urology 2000;55(5A Suppl):60-4.
127. McInerney PD, Grant A, Chawla J, Stephenson TP. The effect of intravesical Marcain instillation on hyperreflexic detrusor contractions. Paraplegia 1992 Feb;30(2):127-30.
128. Kim DY, Chancellor MB. Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol 2000;14:97-103.
129. Finkbeiner AE. Is bethanechol chloride clinically effective in promoting bladder emptying? A literature review. J Urol 1985;134:443.
130. Weiner WJ, Singer C, Shulman LM. Parkinsonism and Parkinson's disease. N Engl J Med 1996;13:1611.
131. Manfredi M, Stocchi F, Vacca L. Differential diagnosis of parkinsonism. J Neural Transm Suppl 1995;45:1-9.
132. de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S21-3.
133. Ross GW, Petrovitch H. Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease. Drugs Aging 2001;18(11):797-806.
134. Yamamoto M. Depression in Parkinson's diseae: its prevalence, diagnosis and neurochemical background. J Neurol 2001;248(Suppl 3):1115-11.
135. Awerbuch GI, Sandyk R. Autonomic functions in the early stages of Parkinson's disease. Int J Neurosci 1994 Jan-Feb;74(1-4):9-16.
136. Turkka JT, Myllyla VV. Sweating dysfunction in Parkinson's disease. Eur Neurol 1987;26:1-7.
137. Koike Y, Takahashi A. Autonomic dysfunction in Parkinson's disease. Eur Neurol 1997;38(Suppl 2):8-12.
138. Nimi Y, Ieda T, Hirayama M, et al. Clinical and physiological characteristics of autonomic failure with Parkinson's disease. Clin Anton Res 1999 Jun;9(3):139-44.
139. Terao Y, Takeda K, Sakuta M, et al. Pure progressive autonomic failure: a clinicopathological study. Eur Neurol 1993;33(6):409-15.
140. Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease-a retrospective comparison. Acta Neurol Scand 1995 Feb;91(2):98-102.
141. Kirby R, Fowler C, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol, Neurosurg, Psychiatry 1986;49:554-62.
142. Yoshimura N, Sasa M, Yoshida O, Takaoria S. Dopamine D-1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol Urodyn 1992;11:535-45.
143. Yoshimura N, Mizuta E, Kuno S, et al. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 1993Apr;32(4):315-21.
144. Aranda B, Cramer P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 1993;12(3):203-9.
145. Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson's disease. J Urol 1987;138(4):836-8.
146. Harvey MA, Baker K, Wells GA. Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol 2001;185:56-61.
147. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ. Neurourologic findings in Parkinson's disease. J Urol 1983a;129:80-3.
148. Stocchi F, Carbone A, Inghilleri M, et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 1997;62:507-11.
149. Gray R, Stern G, Malone-Lee J. Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Aging 1995;24:499-504.
150. Lemack GE, Dewey RB Jr, Roehrborn CG, et al. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000 Augl;56(2):250-4.
151. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurosurg Psychiatry 2000b;68:429-33.
152. Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson's disease. Eur Neurol 1992;32(3):134-40.
153. Korczyn AD. Dementia in Parkinson's disease. J Neurol 2001;248(Suppl 3):III1-4.
154. Galloway NT. Urethral sphincter abnormalities in Parkinsonism. Br J Urol 1983;55:691-3.
155. Sakakibara R, Hattori T, Uchiyama T, et al. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2001;71:600-6.
156. Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997;20:1396-403.
157. Pramstaller PP, Wenning GK, Smith SJ, et al. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58:618-21.
158. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988 Dec;38(12):1841-4.
159. Nakashima K, Maeda M, Tabata M, et al. Prognosis of Parkinson's disease in Japan. Tottori University Parkinson's Disease Epidemiology (TUPDE) Study Group. Eur Neurol 1997;38 (Suppl 2):60-3.
160. Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48:384-93.
161. Rinne UK. Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 1981;51:161-74.
162. Yoshimura N, Mizuta E, Yoshida O, Kuno S. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 1998;286(1):228-33.
163. Kuno S, Mizuta E, Yoshimura N. Differential effects of D1 and D2 agonists on neurogenic bladder in Parkinson's disease and MPTP-induced parkinsonian monkeys. Mov Disord Suppl 1998;12:1.
164. Staskin DR, Vardi Y, Siroky MB. Postprostatectomy incontinence in the Parkinsonian patient: The significance of poor voluntary sphincter control. J Urol 1988;140:117.
165. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997Jul;80(1):100-4.
166. Khan Z, Starer P, Bhola A. Urinary incontinence in female Parkinson disease patients. Pitfalls of diagnosis. Urology 1989 Jun;33(6):486-9.
167. Araki I, Kitahara M, Tomoyuki O, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol 2000a;164:1640-3.